Correction: Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study
Doris K. Hansen, Danai Dima, Hira Mian, Jakob Devos et autres
0 citationsBlood Cancer Journal
Binod Dhakal
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
374Publications signalées
5659Citations signalées
1Affiliations récentes
Institutions déclarées
Domaines associés
Multiple Myeloma Research and TreatmentsCAR-T cell therapy researchProtein Degradation and InhibitorsChronic Lymphocytic Leukemia ResearchHematopoietic Stem Cell Transplantation
Publications récentes
Older and frail patients with multiple myeloma treated with bispecific antibodies: A systematic review and meta‐analysis
Hafsa M. Gundroo, Elham Nasrollahi, Becky Alford, Binod Dhakal et autres
0 citationsBritish Journal of Haematology
Immune effector cell associated hematotoxicity (ICAHT) with BCMA CAR T cell therapy in the earlier lines
Meera Mohan, Anushareddy Muddasani, Hayder Alkhalisy, Lisa Rein et autres
0 citationsBlood Cancer Journal
Redefining functional high‐risk multiple myeloma in the context of upfront quadruplet therapy and autologous stem cell transplantation
Gayathri Ravi, Binod Dhakal, Natalie S. Callander, Eva Medvedova et autres
1 citationCancer
Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial
Hermann Einsele, J. San‐Miguel, Binod Dhakal, Cyrille Touzeau et autres
41 citationsThe Lancet Oncology
Plasma cell leukemia: genomic features and their potential relevance for exploring clinical actionability
Meera Mohan, Natalie Danziger, Othman Salim Akhtar, Ravi Narra et autres
2 citationsBlood Advances
Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials
Brandi Reeves, Saurabh Chhabra, Robert F. Cornell, Cesar Rodriguez et autres
0 citationsCarolina Digital Repository (University of North Carolina at Chapel Hill)
Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study
Samer Al Hadidi, Anikó Szabó, Bhavesh Mohan Lal, Aishee Bag et autres
19 citationsBlood Cancer Journal
Ultra high-risk multiple myeloma with early mortality despite quad-class and BCMA-directed therapies: Clinical and molecular insights
Binod Dhakal, Maria Hintzke, Othman Salim Akhtar, Jamila Mammadova et autres
0 citationsBlood
Kinetics of circulating multiple myeloma cells (CMMCs) in patients undergoing standard-of-care anti-BCMA chimeric antigen receptor T cell therapy for Relapsed/Refractory multiple myeloma
Michael Slade, Julie Fortier, Mark A. Fiala, Binod Dhakal et autres
1 citationBlood
Outcomes of stem cell boost (SCB) versus supportive care alone for prolonged cytopenias after chimeric antigen receptor T cell therapy (CAR-T) in relapsed/refractory multiple myeloma (RRMM): A muli-center real-world analysis
Cindy Varga, Myra Robinson, James A. Davis, Hamza Hashmi et autres
3 citationsBlood
Redefining function high-risk (FHR) multiple myeloma (MM) in the context of upfront quadruplet (QUAD) therapy and autologous stem cell transplantation (ASCT)
Luciano J. Costa, Susan Bal, Kelly Godby, Gayathri Ravi et autres
1 citationBlood
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.